×
Skip to content
ShareCafe

  • Home
  • Shares
  • Financial Products
  • Video
  • Contributors
  • Community
  • About us
  • Facebook
  • Twitter
  • YouTube
  • RSS
Main Menu

Alison Savas

Alison Savas represents the Antipodes investment team as client portfolio manager. Prior to joining Antipodes Alison was an investment analyst with Smith Tan Asset Management in Singapore and a deputy portfolio manager at Kingfisher Investments, a Singapore-based family office. From 2004 to 2015 Alison was a senior investment analyst at Platinum Asset Management where she covered a range of sectors in Asia, with a focus on India, ASEAN and South Korea. After being selected in the Commonwealth Bank of Australia’s graduate program Alison commenced her investment career at AspectHuntley (now Morningstar) as an associate analyst with responsibility for a portfolio of Australian small cap stocks. Alison holds a Bachelor of Commerce with majors in Finance and Accounting from the University of New South Wales.

Commodities / Funds / Markets

Why We’re Adding Exposure to the Natural Gas Sector

December 1, 2021December 1, 2021 - by Alison Savas

A compelling supply demand equation is emerging for the natural gas sector which could set the foundations for a significant multi-year hydrocarbon cycle.

Read More
Funds / Markets

The Three Big Topics Dominating Global Equity Markets

October 28, 2021October 28, 2021 - by Alison Savas

Three key issues – inflation, the power crunch, and China’s economy – reverberated during the third quarter of 2021 and continue to present a complex backdrop for global equity investors.

Read More
ESG / Funds / Markets

ESG: Driving Change and Generating Alpha

September 21, 2021September 21, 2021 - by Alison Savas

The focus on investing through an ESG lens has intensified. But, as Antipodes’ Alison Savas argues, it’s not as simple as buying stocks with ‘green credentials’, or divesting those with poor backward-looking metrics.

Read More
Funds / Markets

Value Across the Market Spectrum

August 25, 2021August 25, 2021 - by Alison Savas

When taking a pragmatic approach, value can be found right across the market spectrum – even in big tech – by identifying resilient businesses that are cheap relative to their growth profile and peers.

Read More
Economics / Fixed Interest / Funds / Interest Rates / Markets

Challenging the Inflation Consensus

May 26, 2021May 27, 2021 - by Alison Savas

Alison Savas from Antipodes looks at both sides of the inflation debate, the structural drivers that could lead to higher inflation and how Antipodes is positioning for inflation.

Read More
Funds / Markets

Slowly, but Surely – the Emergence of New Market Leaders

April 27, 2021April 27, 2021 - by Alison Savas

Alison Savas from Antipodes runs through her thoughts on the world’s markets at present, where the risks lie, and how the Antipodes Global Fund’s portfolio is currently positioned.

Read More
  • All Wheat and No Chaff for GrainCorp
  • CBA Earnings Hit 4-Year High on Improved Loan Book
  • Are We There Yet?
  • Market Takes the Long Stick to St Barbara
  • 12 Charts We’re Thinking About Right Now
  • Musk Takes More off the Top with Tesla Sales
  • Lunch Report: 10 August, 2022
  • Markets await tomorrow’s US CPI data

Subscribe to ShareCafe

The daily resource for hands-on investors. Market insights and investment ideas delivered free to your inbox.

Copyright 2020 Informed Investor Pty Ltd ABN 42 162 871 589. All rights reserved.
No portion of this website maybe reproduced, copied or in any way released without written permission.
Share Cafe is a Corporate Authorised Representative (001283561) of Sequoia Asset Management Pty Limited who holds an Australian Financial Services Licence (Number: 341506)

Terms of Service | Privacy Policy | Contact | Advertise

DOWNLOAD RESEARCH REPORT

Paxalisib Misses AGILE Hurdle, but Very Significant Value Remains

Investors Over-React, Smart Ones Will Profit

Kazia Therapeutics (KZA) announced yesterday morning that paxalisib did not meet the threshold to move into stage 2 of the GBM AGILE clinical trial (NCT03970447). The study was an adaptive trial designed to assess the potential of new therapeutics to treat the highly aggressive brain cancer glioblastoma (GBM) in a cost-effective manner. Demonstrating efficacy in GBM is an extremely high hurdle as shown by the fact that there is only one approved drug for the disease, temozolomide, and it is only effective in 1/3 of patients.

Given the high nature of the hurdle, in our original initiating coverage report on KZA, we only gave paxalisib a small chance of returning a positive result from the overall study. That is the nature of drug development with one group estimating only 6% to 7% of new chemical entities that commence clinical trials reach launch (Dowden & Munro (2019) Nat Rev Drug Discov). The small percentage that do make it to launch, however, more than make up for the cash spent on those that don’t.

    SMSFBrokerFinancial Adviser

    Please prove you are human by selecting the House.

    DOWNLOAD RESEARCH REPORT

    The Cash keeps coming

    Terracom will report their FY2022 results in September 2022. In the last two months there have been a number of company announcements that have given us improved visibility on our earnings forecasts and valuation metrics so we have taken this opportunity to update our numbers.

    With the combination of geopolitical factors in the northern hemisphere as well as disruption from other supply regions, we believe the visibility on export coal prices over the next 12 months has also improved since our March note.

      SMSFBrokerFinancial Adviser

      Please prove you are human by selecting the Car.

      DOWNLOAD RESEARCH REPORT

      Acquisitions underpin strong near term growth opportunities not reflected in share price

      Stealth Global Holdings (SGI) provides direct exposure to the growing industrial consumables market, driven by favourable conditions across key industries, expanding industrialisation and improving workplace safety regulations. Around 95% of revenue is attributable to non-discretionary items.

      Based on our current forecasts, we derive a DCF equity value for SGI of $0.33 per share, with potential upside if full synergies can be extracted. We note SGI is currently trading on very undemanding forward multiples.

        SMSFBrokerFinancial Adviser

        Please prove you are human by selecting the Plane.

        DOWNLOAD RESEARCH REPORT

        4Q reveals more focus on profit and cash flow

        • LBY’s 4Q FY22 quarterly activities update showed continued solid growth in top line metrics, albeit slowing, with GMV of NZ$203m (+26% on pcp) and income of NZ$12.1m (+23% on pcp).
        • Net Transaction Margin (NTM) disappointed at -0.5%, due to further increase in credit losses from 4.0% to 4.9% of GMV. However, new fraud and credit risk management tools have seen losses recover materially with NTM back to 1.2% in March and LBY is confident of further recovery in coming months.

          SMSFBrokerFinancial Adviser

          Please prove you are human by selecting the Car.

          DOWNLOAD RESEARCH REPORT

          Signs MOU with Ford Company – Kachi is now sold out!

          Lake Resources (LKE. ASX) – LKE has signed two non-binding MOU’s in the space of 10 days. Ford Company (Ford) has signed an MOU for ~25,000t/year and last week Hanwa, a Japanese commodity trader signed a MOU for up to 25,000t/year. Subject to execution, this is an amazing feat as Ford and Hanwa are prepared to enter into longer-term strategic partnerships with LKE. Commercial negotiations are still ongoing but are expected, especially if Ford & Hanwa inject new equity into LKE, to further de-risk the project financing & thus ensure LKE and Kachi are fully funded.

            SMSFBrokerFinancial Adviser

            Please prove you are human by selecting the Tree.

            DOWNLOAD RESEARCH REPORT

            Strategic Vanadium-battery growth with Titanium & Iron earnings resiliency

            TNG Ltd is an ASX-listed technology owner and developer of the world-class Mount Peake near-surface vanadiferous titanomagnetite deposit. To unlock value, TNG will concentrate ore from its central Northern Territory mine for processing through its patented TIVAN® process produce three premium quality revenue streams: hi-purity vanadium pentoxide (V2O5) for steel alloys and Vanadium Redox Flow batteries, a quality titanium pigment for paints and a premium steel input with >64%Fe iron ore fines.

              SMSFBrokerFinancial Adviser

              Please prove you are human by selecting the Car.

              Promising exploration and development update while SOP prices continue to rise

              Two recent gravity surveys have considerably exceeded expectations and revealed potential for extensions to the existing MRE at Lake Throssell, plus a material growth opportunity at Lake Yeo. This reinforces the potential for a multi-decade, Tier-1 SOP production hub based around Lake Throssell.

              TMG is currently completing work towards the PFS due early 2023, including drilling to start in Q3 2022, evaporation trials and permitting activities. Results from these programs will support the PFS and any future resource upgrade.

              Benchmark SOP prices have risen to ~US$940/t due to recent geopolitical developments. The Oct 2021 Scoping Study assumed a SOP price of US$550/t and contained a sensitivity analysis showing every 10% increase in price drives a +$144m increase in the project NPV of $364m. The c.70% increase above the Scoping Study thus implies a project NPV of ~$1.4bn.

              DOWNLOAD RESEARCH REPORT

                SMSFBrokerFinancial Adviser

                Please prove you are human by selecting the Star.

                DOWNLOAD RESEARCH REPORT

                Biopharmas Hit, but Buying Opportunities Created

                The news being reported about the performance of biotechnology has been dour, to say the least, for some time now. Those dour articles have been deserved with the iShares Biotechnology Exchange-Traded Fund down 25% and the SPDR® S&P® Biotech ETF is down 45% from their highs. However, those articles are backward-looking, and successful investors need to be looking forward.

                Recently, however, an article in Nature Reviews Drug Discovery caught our eye which we believe should point the way forward for the vast majority of Australian biotechnology investors. This article indicates that, at least, two companies, Antisense Therapeutics (ANP) and Kazia Therapeutics (KZA), are right in the sweet spot in terms of the future of drug development.

                  SMSFBrokerFinancial Adviser

                  Please prove you are human by selecting the House.

                  DOWNLOAD RESEARCH REPORT

                  Hitting goals – Making four material announcements

                  We initiated on Magnis Energy Technologies (MNS.ASX) in December 2021 and since then, MNS has made four material announcements. Firstly; a conditional offtake contract for 600,000t of graphite concentrate from the Tanzanian Nachu Project (net 100%) was signed with Traxys, a global
                  commodities merchant with annual revenue of ~US$6Bn; secondly; semi autonomous production has started at battery gigafactory iM3NY, thirdly;
                  exciting Extra Fast Charge battery tests were reported and most recently, the game changing launch of the Lithium Slim Energy Reserve battery platform, which supports C4V’s growing EFC capability.

                    SMSFBrokerFinancial Adviser

                    Please prove you are human by selecting the Plane.

                    DOWNLOAD RESEARCH REPORT

                    Increasing our Target

                    Despite the lower realised oil and gas price, which fell by 5.4% and 19.7% respectively in August, Calima managed to show improvement in its key business metrics.

                    We expect higher production in November due to the contribution by the new Thorsby wells which will be drilled in August/September which will see Calima meet its 2021 production guidance of 4,500 boe/d.

                      SMSFBrokerFinancial Adviser

                      Please prove you are human by selecting the House.

                      DOWNLOAD RESEARCH REPORT

                      Emerging Financial Wealth Advisory Group

                      WT Financial Group Limited (WTL) is a growing diversified financial services company, founded in 2010 and listed on the Australian Stock Exchange (ASX) in 2015. Its advice and product offerings are delivered primarily through a group of independent financial advisers operating as authorised representatives of WTL under its Wealth Today Pty Ltd (Wealth Today) and Sentry Group Pty Ltd (Sentry Group) dealer group operations. It has around 275 advisers across more than 200 financial advice practices Australia-wide. It also operates a direct-to-consumer operation under its Spring Financial Group brand.

                        SMSFBrokerFinancial Adviser

                        Please prove you are human by selecting the House.

                        DOWNLOAD RESEARCH REPORT
                        Immutep Taking the Fight to Cancer

                        In May 2021, Corporate Connect analyst Marc Sinatra published a comprehensive research report on ASX-listed biotech Immutep Ltd (ASX: IMM). So impressed was he with IMM that Corporate Connect felt it imperative that a follow-up report be released placing a valuation on the company, because the market was not seeing the vast potential of eftilagimod alpha (efti).

                        This follow-up report has been released today. Using comparables, after adding cash back to their EV estimate and dividing by the total number of issued shares, Corporate Connect now places the fair value of an Immutep share at $A2.20.

                          SMSFBrokerFinancial Adviser

                          Please prove you are human by selecting the Flag.

                          DOWNLOAD RESEARCH REPORT

                          Phillips 66 to acquire 16% in NVX – 12-month target price rises 7% through project de-risking

                          Phillips 66 (PSX) has entered into an agreement with NVX to acquire 77.9m new shares for US$150m (A$203m). PSX is the worlds largest producer of speciality petroleum coke a precursor for battery grade synthetic graphite anode materials found with an Enterprise Value of US$47.5Bn and assets of US$57Bn.

                            SMSFBrokerFinancial Adviser

                            Please prove you are human by selecting the Truck.

                            DOWNLOAD RESEARCH REPORT

                            Market leading lifelong learning platform technology company in Australia and SE Asia

                            PayGroup (PYG) delivers multi-country BPO services and cloud SaaS HCM solutions, assisting companies to manage employees in multiple, complex jurisdictions. The company has many growth opportunities, including new clients, new jurisdictions, new products, partner expansion, and new revenue sources. PYG’s scalable business model allows operating leverage and with savings from in-housing third party technology, support margin expansion.

                              SMSFBrokerFinancial Adviser

                              Please prove you are human by selecting the Flag.

                              DOWNLOAD RESEARCH REPORT

                              Market leading lifelong learning platform technology company in Australia and SE Asia

                              OpenLearning (OLL) is a higher education technology company that operates a scalable online learning platform through a software-as-a-service (SaaS) business model and provides a global marketplace of high quality courses for learners of all levels. Its primary customers are education providers based in Australia and South-East Asia (primarily Malaysia). OLL started operations in Australia in 2012 and expanded to Malaysia in 2015, Singapore in 2018, and recently also Indonesia.

                                SMSFBrokerFinancial Adviser

                                Please prove you are human by selecting the Cup.